224 related articles for article (PubMed ID: 26697973)
1. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine.
Rudenko L; Naykhin A; Donina S; Korenkov D; Petukhova G; Isakova-Sivak I; Losev I; Stukova M; Erofeeva M; Nikiforova A; Power M; Flores J
Hum Vaccin Immunother; 2015; 11(12):2839-48. PubMed ID: 26697973
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial.
Pitisuttithum P; Boonnak K; Chamnanchanunt S; Puthavathana P; Luvira V; Lerdsamran H; Kaewkungwal J; Lawpoolsri S; Thanachartwet V; Silachamroon U; Masamae W; Schuetz A; Wirachwong P; Thirapakpoomanunt S; Rudenko L; Sparrow E; Friede M; Kieny MP
Lancet Infect Dis; 2017 Aug; 17(8):833-842. PubMed ID: 28533093
[TBL] [Abstract][Full Text] [Related]
3. A live attenuated H5N2 prime- inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses.
Kongchanagul A; Samnuan K; Wirachwong P; Surichan S; Puthavathana P; Pitisuttithum P; Boonnak K
Vaccine; 2020 Jan; 38(4):852-858. PubMed ID: 31708176
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of in vitro cross-reactivity to avian H5N1 and pandemic H1N1 2009 influenza following prime boost regimens of seasonal influenza vaccination in healthy human subjects: a randomised trial.
Bethell D; Saunders D; Jongkaewwattana A; Kramyu J; Thitithayanont A; Wiboon-ut S; Yongvanitchit K; Limsalakpetch A; Kum-Arb U; Uthaimongkol N; Garcia JM; Timmermans AE; Peiris M; Thomas S; Engering A; Jarman RG; Mongkolsirichaikul D; Mason C; Khemnu N; Tyner SD; Fukuda MM; Walsh DS; Pichyangkul S
PLoS One; 2013; 8(3):e59674. PubMed ID: 23555741
[TBL] [Abstract][Full Text] [Related]
5. Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes.
Jegaskanda S; Mason RD; Andrews SF; Wheatley AK; Zhang R; Reynoso GV; Ambrozak DR; Santos CP; Luke CJ; Matsuoka Y; Brenchley JM; Hickman HD; Talaat KR; Permar SR; Liao HX; Yewdell JW; Koup RA; Roederer M; McDermott AB; Subbarao K
J Virol; 2018 May; 92(9):. PubMed ID: 29444938
[TBL] [Abstract][Full Text] [Related]
6. Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.
Gillard P; Chu DW; Hwang SJ; Yang PC; Thongcharoen P; Lim FS; Dramé M; Walravens K; Roman F
BMC Infect Dis; 2014 Mar; 14():142. PubMed ID: 24628789
[TBL] [Abstract][Full Text] [Related]
7. Heterosubtypic protection against avian influenza virus by live attenuated and chimeric norovirus P-particle-M2e vaccines in chickens.
Ghorbani A; Ngunjiri JM; Xia M; Elaish M; Jang H; Mahesh KC; Abundo MC; Jiang X; Lee CW
Vaccine; 2019 Feb; 37(10):1356-1364. PubMed ID: 30691981
[TBL] [Abstract][Full Text] [Related]
8. Influenza H5 hemagglutinin DNA primes the antibody response elicited by the live attenuated influenza A/Vietnam/1203/2004 vaccine in ferrets.
Suguitan AL; Cheng X; Wang W; Wang S; Jin H; Lu S
PLoS One; 2011; 6(7):e21942. PubMed ID: 21760928
[TBL] [Abstract][Full Text] [Related]
9. Cell culture (Vero cell) derived whole-virus non-adjuvanted H5N1 influenza vaccine induces long-lasting cross-reactive memory immune response: homologous or heterologous booster response following two dose or single dose priming.
van der Velden MV; Aichinger G; Pöllabauer EM; Löw-Baselli A; Fritsch S; Benamara K; Kistner O; Müller M; Zeitlinger M; Kollaritsch H; Vesikari T; Ehrlich HJ; Barrett PN
Vaccine; 2012 Sep; 30(43):6127-35. PubMed ID: 22884662
[TBL] [Abstract][Full Text] [Related]
10. High-Affinity H7 Head and Stalk Domain-Specific Antibody Responses to an Inactivated Influenza H7N7 Vaccine After Priming With Live Attenuated Influenza Vaccine.
Halliley JL; Khurana S; Krammer F; Fitzgerald T; Coyle EM; Chung KY; Baker SF; Yang H; Martínez-Sobrido L; Treanor JJ; Subbarao K; Golding H; Topham DJ; Sangster MY
J Infect Dis; 2015 Oct; 212(8):1270-8. PubMed ID: 25838266
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I-II clinical trials).
Rudenko L; Desheva J; Korovkin S; Mironov A; Rekstin A; Grigorieva E; Donina S; Gambaryan A; Katlinsky A
Influenza Other Respir Viruses; 2008 Nov; 2(6):203-9. PubMed ID: 19453396
[TBL] [Abstract][Full Text] [Related]
12. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination.
Levine MZ; Martin JM; Gross FL; Jefferson S; Cole KS; Archibald CA; Nowalk MP; Susick M; Moehling K; Spencer S; Chung JR; Flannery B; Zimmerman RK
Clin Vaccine Immunol; 2016 Oct; 23(10):831-839. PubMed ID: 27558294
[TBL] [Abstract][Full Text] [Related]
14. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response.
Talaat KR; Luke CJ; Khurana S; Manischewitz J; King LR; McMahon BA; Karron RA; Lewis KD; Qin J; Follmann DA; Golding H; Neuzil KM; Subbarao K
J Infect Dis; 2014 Jun; 209(12):1860-9. PubMed ID: 24604819
[TBL] [Abstract][Full Text] [Related]
15. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a vero cell culture-derived whole-virus H5N1 influenza vaccine in chronically ill and immunocompromised patients.
van der Velden MV; Geisberger A; Dvorak T; Portsmouth D; Fritz R; Crowe BA; Herr W; Distler E; Wagner EM; Zeitlinger M; Sauermann R; Stephan C; Ehrlich HJ; Barrett PN; Aichinger G
Clin Vaccine Immunol; 2014 Jun; 21(6):867-76. PubMed ID: 24739978
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women.
Brady RC; Jackson LA; Frey SE; Shane AL; Walter EB; Swamy GK; Schlaudecker EP; Szefer E; Wolff M; McNeal MM; Bernstein DI; Steinhoff MC
Vaccine; 2018 Jul; 36(31):4663-4671. PubMed ID: 29961606
[TBL] [Abstract][Full Text] [Related]
18. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.
Vesikari T; Forstén A; Borkowski A; Gaitatzis N; Banzhoff A; Clemens R
Hum Vaccin Immunother; 2012 Jul; 8(7):921-8. PubMed ID: 22777094
[TBL] [Abstract][Full Text] [Related]
19. Live attenuated and inactivated influenza vaccines in children.
Ilyushina NA; Haynes BC; Hoen AG; Khalenkov AM; Housman ML; Brown EP; Ackerman ME; Treanor JJ; Luke CJ; Subbarao K; Wright PF
J Infect Dis; 2015 Feb; 211(3):352-60. PubMed ID: 25165161
[TBL] [Abstract][Full Text] [Related]
20. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine.
Babu TM; Levine M; Fitzgerald T; Luke C; Sangster MY; Jin H; Topham D; Katz J; Treanor J; Subbarao K
Vaccine; 2014 Nov; 32(50):6798-804. PubMed ID: 25446831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
